Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.65
- Piotroski Score 1.00
- Grade Neutral
- Symbol (ALIM)
- Company Alimera Sciences, Inc.
- Price $5.54
- Changes Percentage (0%)
- Change -$0
- Day Low $5.54
- Day High $5.55
- Year High $5.65
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/24/2024
- Fiscal Year End N/A
- Average Stock Price Target $5.75
- High Stock Price Target $6.00
- Low Stock Price Target $5.50
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.25
- Trailing P/E Ratio -12.04
- Forward P/E Ratio -12.04
- P/E Growth -12.04
- Net Income $-20,132,000
Income Statement
Quarterly
Annual
Latest News of ALIM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is TAV Havalimanlari Holding AS (TAVHF) a Good Airport Stock To Add To Your Portfolio?
A comprehensive analysis of the airport industry highlights TAV Havalimanlari Holding AS as a leading player. With a focus on sustainability and growth, the company's recent achievements and financial...
By Yahoo! Finance | 1 week ago -
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
Johnson & Johnson submitted a BLA to the FDA for nipocalimab, a potential treatment for generalized myasthenia gravis. Data from the Vivacity-MG3 study showed sustained disease control in gMG patients...
By Yahoo! Finance | 1 month ago -
Billionaire Salim-Backed PIK 2 Doubles Down On $2.6 Billion Indonesian Tourism Estate Project
PIK 2, a property developer in Indonesia backed by Anthoni Salim and Sugianto Kusuma, is expanding its 40 trillion rupiah tourism estate project. The company raised $420 million for the project, showi...
By Forbes | 1 month ago
